Arbutus Biopharma Announces Presentation Of Imdusiran Data At EASL Congress 2024

Key Findings: HBsAg ≤ LLOQ (lower limit of quantification) with detectable anti-HBs was observed at end-of-treatment in 28% of subjects who received 4 or 6 doses of imdusiran plus 24 weeks of IFN, but in 0 subjects who received 4 or 5 doses of imdusiran plus 12 weeks of IFN. The study remains ongoing and additional end-of-treatment data, durability of end-of-treatment HBsAg loss, and preliminary immunology data for a subset of study subjects will be presented.